Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

Standard Dose
EQ 300MG BASE;150MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is listed in Drugs@FDA under application 202912 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE Form and strength TABLET;ORAL - EQ 300MG BASE;150MG;300MG Sponsor LUPIN LTD Submission history Latest submission status date: 2022-04-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is listed in Drugs@FDA under application 202912 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE Form and strength TABLET;ORAL - EQ 300MG BASE;150MG;300MG Sponsor LUPIN LTD Submission history Latest submission status date: 2022-04-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.